Outsourcing-pharma1d
Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
GlobalData on MSN1d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...